Effect of long-term oral administration of nicotinamide mononucleotide (NMN) on human health
Not Applicable
- Conditions
- Healthy volunteers
- Registration Number
- JPRN-UMIN000025739
- Lead Sponsor
- Hiroshima University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
1) Taking medicines for chronic disease 2) Taking functional food that may affect the trial 3) Participation in any clinical trial within 90 days of the commencement of the trial 4) History of hypersensitivity caused by NMN 5) In pregnancy or nursing a child 6) Judged as ineligible by clinical investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method i) Serum or plasma concentration of the following parameters at baseline, weeks 4, 8, 12, 18, and 24. *Thyroid-stimulating hormone (TSH) *Free triiodothyronine (Free T3) *Free thyroxine (Free T4) *Growth hormone (GH) *Prolactin *Parathyroid hormone (PTH) *Dehydroepiandrosterone sulfate (DHEA-S) *Estradiol (E2) *Testosterone *Calcitonin *Adrenocorticotropic hormone (ACTH) *Arginine vasopressin (AVP) *Cortisol *Aldosterone *Ghrelin *Inhibin *Melatonin ii) Mitochondria activity in leucocyte at baseline and week 24. iii) Sirt1 and Sirt2 gene expressions in leucocyte at baseline and week 24.
- Secondary Outcome Measures
Name Time Method umber and rate of adverse events.